Mesoblast (ASX:MSB) has welcomed new research showing that its allogeneic cell therapy remestemcel-L delivers superior clinical outcomes compared with ruxolitinib for patients with steroid-refractory acute graft versus host disease. …
New analysis finds Mesoblast’s Remestemcel-L outperforms ruxolitinib in severe GvHD
December 14, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
It is profoundly wrong for any system to exclude compassion while outsourcing it to others
March 16, 2026 - - Latest News -
Scientists identify highly specific targets that could transform multiple myeloma treatment
March 15, 2026 - - Australian Biotech -
CSL Seqirus' adjuvanted flu vaccine approval extended to Australians aged 50 and over
March 15, 2026 - - Latest News -
GSK claims Pharma Cup as Kosi Challenge surpasses fundraising record
March 15, 2026 - - Latest News -
New program aims to make women’s health care more affordable and accessible
March 13, 2026 - - Latest News -
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News